<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442324</url>
  </required_header>
  <id_info>
    <org_study_id>2252P</org_study_id>
    <nct_id>NCT01442324</nct_id>
  </id_info>
  <brief_title>Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer &amp; Cholangiocarcinoma</brief_title>
  <official_title>Studio Clinico Pilota Con Uso di Elettroporazione Irreversibile (IRE) Nel Trattamento di Lesioni Neoplastiche Epatiche Con Localizzazione ad accessibilità Limitata o ad Alto Rischio</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera di Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm pilot clinical trial. Patients will be subjected to irreversible electroporation
      (IRE) as the sole treatment of nodules not considered treatable by resection or thermal
      ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-arm pilot clinical trial. Patients will be subjected to irreversible electroporation
      (IRE) as the sole treatment of nodules not considered treatable by resection or thermal
      ablation.

      This pilot study was designed to study the feasibility and safety of treatment as an
      alternative therapeutic IRE in the treatment of neoplastic nodules in the liver, with
      particular reference to metastatic liver cancer and cholangiocarcinoma, where the current
      therapeutic arsenal is inadequate or counter-indicated.

      To perform the IRE procedure the IRE NanoKnife™ System (AngioDynamics) will be used.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of IRE for the treatment of metastatic liver cancer or cholangiocarcinoma.</measure>
    <time_frame>1 month post-intervention</time_frame>
    <description>The primary measurement parameter for the purposes of this determination is the evaluation of the response of IRE treated lesions according to modified RECIST criteria using CT images or magnetic resonance imaging performed 20 to 40 days after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>30 days post-intervention</time_frame>
    <description>The safety endpoint will be the occurrence of serious adverse events related to treatment within 30 days of treatment. All adverse events will be classified according to CTCAE version 3.0 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to in situ recurrence</measure>
    <time_frame>2 years post-intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Metastatic Liver Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>IRE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be subjected to irreversible electroporation (IRE) as the sole treatment of nodules not considered treatable by resection or thermal ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Irreversible electroporation (IRE)</intervention_name>
    <description>Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.</description>
    <arm_group_label>IRE</arm_group_label>
    <other_name>NanoKnife™ System</other_name>
    <other_name>AngioDynamics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older than 18 years,

          -  male or female,

          -  diagnosis of secondary liver cancer or cholangiocarcinoma based on positive biopsy or
             noninvasive criteria,

          -  presence of at least one lesion untreatable by surgical resection or ablation for
             microwave or radio frequency,

          -  the target nodule must have a diameter of ≤ 5 cm

          -  ECOG score(Eastern Cooperative Oncology Group) 0,

          -  ASA score (American Society of Anesthesiologists) ≤ 3,

          -  prothrombin time ratio &gt;50%

          -  platelet count &gt;50x10^9/l,

          -  patient's ability to discontinue anticoagulant and antiplatelet therapy for seven days
             before and seven days after surgery with NanoKnife™,

          -  ability to understand and willingness to sign the written informed consent form (ICF),

          -  life expectancy of at least 3 months.

        Exclusion Criteria:

          -  presence of more than 5 liver lesions,

          -  previous treatment of the target nodule,

          -  patient received systemic chemotherapy within 30 days of treatment with the IRE
             NanoKnife™,

          -  heart failure, coronary artery disease or arrhythmia in progress, active implantable
             devices (eg pacemaker),

          -  pregnant women or women of childbearing potential not using an acceptable method of
             contraception,

          -  patient undergoing treatment with an investigational drug within 30 days of treatment
             with the IRE NanoKnife™,

          -  in the opinion of the researcher, anyone who can not follow the calendar of visits and
             assessments of the Protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Cillo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Vitale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Umberto Cillo, MD</last_name>
    <phone>+390498218624</phone>
    <email>cillo@unipd.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Vitale, MD</last_name>
    <phone>+390498218624</phone>
    <email>alessandro.vitale@unipd.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>I-35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Cillo, MD</last_name>
      <phone>+390498218624</phone>
      <email>ciilo@unipd.it</email>
    </contact>
    <contact_backup>
      <last_name>Alessandro Vitale, MD</last_name>
      <phone>+390498218624</phone>
      <email>alessandro.vitale@unipd.it</email>
    </contact_backup>
    <investigator>
      <last_name>Umberto Cillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Vitale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fegatochirurgia.com</url>
    <description>Hepatobiliary surgery and Liver Transplantation Unit, University Hospital of Padua (Italy)</description>
  </link>
  <reference>
    <citation>Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in &quot;out of operating theater&quot; anesthesia. Anesth Analg. 2010 May 1;110(5):1305-9. doi: 10.1213/ANE.0b013e3181d27b30. Epub 2010 Feb 8.</citation>
    <PMID>20142349</PMID>
  </reference>
  <reference>
    <citation>Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007 Aug;6(4):295-300.</citation>
    <PMID>17668936</PMID>
  </reference>
  <reference>
    <citation>Esser AT, Smith KC, Gowrishankar TR, Weaver JC. Towards solid tumor treatment by irreversible electroporation: intrinsic redistribution of fields and currents in tissue. Technol Cancer Res Treat. 2007 Aug;6(4):261-74.</citation>
    <PMID>17668933</PMID>
  </reference>
  <reference>
    <citation>Al-Sakere B, André F, Bernat C, Connault E, Opolon P, Davalos RV, Rubinsky B, Mir LM. Tumor ablation with irreversible electroporation. PLoS One. 2007 Nov 7;2(11):e1135.</citation>
    <PMID>17989772</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera di Padova</investigator_affiliation>
    <investigator_full_name>Prof. Umberto Cillo</investigator_full_name>
    <investigator_title>Director of the Hepatobiliary Surgery and Liver Transplantation Unit</investigator_title>
  </responsible_party>
  <keyword>Laparotomic surgery</keyword>
  <keyword>Laparoscopic surgery</keyword>
  <keyword>Percutaneos tumour ablation</keyword>
  <keyword>Irreversible electroporation (IRE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

